Skip to main content
Premium Trial:

Request an Annual Quote

Iain Mattaj to Succeed Fotis Kafatos at EMBL s Helm

NEW YORK, June 29 (GenomeWeb News) - The European Molecular Biology Laboratory said today that it has chosen Iain Mattaj to serve as director-general following the departure of Fotis Kafatos, whose term ends next May.

 

Mattaj joined EMBL in 1985, and was appointed scientific director for the organization in 1999. His early research focused on assemblies of RNA and protein in the cell, and he characterized mechanisms of macromolecular transport between the nucleus and the cytoplasm.

 

EMBL elected Mattaj after an international search by a committee appointed by the EMBL Council, which represents the laboratory's 17 member states and five locations.

 

Mattaj will be EMBL's fourth director-general since the laboratory was founded in 1974.

 

"[T]he pace of progress in the life sciences is remarkable," Mattaj said in a statement. "The rate of change and the evolution of ideas within the laboratory need to match this pace, and I will have to ensure that they do. I look forward to this challenge."

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.